Skip to content
Screener

Net Income at other companies

Pfizer logo
PfizerPFE
-$248M-109%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.89M-102%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$73.5M-29.9%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$120.85M-4.8%
Cytokinetics logo
CytokineticsCYTK
-$198.76M-47.9%

Segments

By segment

See full
Single Reportable-$40.73M-57.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$42.9M-54.9%
EPS (diluted)-$0.70-22.8%

Balance sheet

See full
Cash & equivalents$20.9M-9.9%
Total debt$91.0M+8,620%
Total equity$246.2M+135%
Total assets$368.7M+176%

Cash flow

See full
Operating cash flow-$31.5M-56.5%
CapEx$4.1M+1,312%
Free cash flow-$35.5M-74.2%

Valuation

See full
Market cap$519.76M+42.6%
Enterprise value$589.87M+64.1%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-73.7%-20.5pp
Debt / equity0.4×+0.4×
Current ratio7.3×+3.0×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Capricor Therapeutics’s 10-Q, filed August 14, 2026.

Filed
Aug 14, 2026, 4:46 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-097294
REVENUE / TOTAL REVENUEThree Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / —Six Months Ended June 30, 2026 / —Six Months Ended June 30, 2025 / —
TOTAL OTHER INCOME (EXPENSE)2,213,5661,808,3435,045,0742,399,697
LOSS BEFORE INCOME TAXES(40,732,054)(25,909,191)(74,673,399)(50,300,785)
(Provision for) benefit from income taxes(1,600)(1,600)(1,600)(1,600)
NET LOSS$(40,733,654)$(25,910,791)$(74,674,999)$(50,302,385)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain (loss) on marketable securities90,186(424,353)(446,695)360,619
COMPREHENSIVE LOSS$(40,643,468)$(26,335,144)$(75,121,694)$(49,941,766)
Net loss per share, basic and diluted$(0.70)$(0.57)$(1.29)$(1.10)

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's net income?
Capricor Therapeutics (CAPR) reported net income of -$40.73M in Q2 2026.
How has Capricor Therapeutics's net income changed year-over-year?
Capricor Therapeutics's net income decreased by 57.2% year-over-year, from -$25.91M to -$40.73M.
What is the long-term trend for Capricor Therapeutics's net income?
Over 4 years (2021 to 2025), Capricor Therapeutics's net income has grown at a 51.3% compound annual growth rate (CAGR), from -$20.02M to -$105.04M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Capricor Therapeutics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude